APC vaccines such as DC vaccines have been shown to enhance TCR-T expansion and tumor suppression following TCR-T cell vaccination; in a study that enrolled 14 HLA-A2.1 + patients with metastatic melanoma, signs of tumor regression were observed in 13 of 14 patients following co-vaccination using genetically modified MART-1 TCR-T cells made from autologous T cells and a MART-1 peptide-pulsed DC vaccine. This evidence concerns the gene MLANA and neoplasm.